The role of mast cells in cancers

F1000Prime Reports

Volumn 7, Issue , 2015, Pages

  Maciel, Thiago T ^a,b,c,d,e   Moura, Ivan C ^a,b,c,d,e   Hermine, Olivier ^a,b,c,d,e,f  

^a INSERM   (France)

^b PARIS DESCARTES SORBONNE PARIS CITÉ UNIVERSITY   (France)

^c CNRS   (France)

^d Laboratory of Excellence GR Ex   (France)

^e Centre de Référence des Mastocytoses AP HP Necker Enfants Malades   (France)

^f HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER GROWTH; CLINICAL TRIAL (TOPIC); HUMAN; MALIGNANT NEOPLASTIC DISEASE; MAST CELL; MOUSE MODEL; NONHUMAN; TUMOR MODEL;

EID: 84921417815     PISSN: 20517599     EISSN: 20517599     Source Type: Journal    
DOI: 10.12703/P7-09     Document Type: Article

References (60)

1. Joyce JA: Therapeutic targeting of the tumor microenvironment. Cancer Cell 2005, 7:513-20.
2. Pagès F, Galon J, Dieu-Nosjean M, Tartour E, Sautès-Fridman C, Fridman W: Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene 2010, 29:1093-102.
3. Pagès F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, Mlecnik B, Kirilovsky A, Nilsson M, Damotte D, Meatchi T, Bruneval P, Cugnenc P, Trajanoski Z, Fridman W, Galon J: Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005, 353:2654-66.
4. Qian B, Pollard JW: Macrophage diversity enhances tumor progression and metastasis. Cell 2010, 141:39-51.
5. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon R, Reed K, Burke MM, Caldwell A, Kronenberg SA, Agunwamba BU, Zhang X, Lowy I, Inzunza HD, Feely W, Horak CE, Hong Q, Korman AJ, Wigginton JM, Gupta A, Sznol M: Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013, 369:122-33.
6. Ribatti D, Crivellato E: Mast cell ontogeny: an historical overview. Immunol Lett 2014, 159:11-4.
7. Galli SJ, Grimbaldeston M, Tsai M: Immunomodulatory mast cells: negative, as well as positive, regulators of immunity. Nat Rev Immunol 2008, 8:478-86.
8. Marshall JS: Mast-cell responses to pathogens. Nat Rev Immunol 2004, 4:787-99.
9. Marichal T, Tsai M, Galli SJ: Mast cells: potential positive and negative roles in tumor biology. Cancer Immunol Res 2013, 1:269-79.
10. Galli SJ, Nakae S, Tsai M: Mast cells in the development of adaptive immune responses. Nat Immunol 2005, 6:135-42.
11. Gurish MF, Austen KF: The diverse roles of mast cells. J Exp Med 2001, 194:F1-5.
12. Marshall JS, McCurdy JD, Olynych T: Toll-like receptor-mediated activation of mast cells: implications for allergic disease? Int Arch Allergy Immunol 2003, 132:87-97.
13. Anders H, Muruve DA: The inflammasomes in kidney disease. J Am Soc Nephrol 2011, 22:1007-18.
14. Ali H: Regulation of human mast cell and basophil function by anaphylatoxins C3a and C5a. Immunol Lett 2010, 128:36-45.
15. Malbec O, Daëron M: The mast cell IgG receptors and their roles in tissue inflammation. Immunol Rev 2007, 217:206-21.
16. Rivera J, Fierro NA, Olivera A, Suzuki R: New insights on mast cell activation via the high affinity receptor for IgE. Adv Immunol 2008, 98:85-120.
17. Blank U, Rivera J: The ins and outs of IgE-dependent mast-cell exocytosis. Trends Immunol 2004, 25:266-73.
18. Sibilano R, Frossi B, Calvaruso M, Danelli L, Betto E, Dall'Agnese A, Tripodo C, Colombo MP, Pucillo CE, Gri G: The aryl hydrocarbon receptor modulates acute and late mast cell responses. J Immunol 2012, 189:120-7.
19. Sibilano R, Pucillo CE, Gri G: Allergic responses and aryl hydrocarbon receptor novel pathway of mast cell activation. Mol Immunol 2014.
20. Maurer M, Theoharides T, Granstein RD, Bischoff SC, Bienenstock J, Henz B, Kovanen P, Piliponsky AM, Kambe N, Vliagoftis H, Levi-Schaffer F, Metz M, Miyachi Y, Befus D, Forsythe P, Kitamura Y, Galli S: What is the physiological function of mast cells? Exp Dermatol 2003, 12:886-910.
21. Rodewald H, Feyerabend TB: Widespread immunological functions of mast cells: fact or fiction? Immunity 2012, 37:13-24.
22. Knol EF, Olszewski M: Basophils and mast cells: Underdog in immune regulation? Immunol Lett 2011, 138:28-31.
23. Kinet JP: The high-affinity IgE receptor (Fc epsilon RI): from physiology to pathology. Annu Rev Immunol 1999, 17:931-72.
24. Bradding P: The role of the mast cell in asthma: a reassessment. Curr Opin Allergy Clin Immunol 2003, 3:45-50.
25. He S: Key role ofmast cells and their major secretory products in inflammatory bowel disease. World J Gastroenterol 2004, 10:309-18.
26. Secor VH, Secor WE, Gutekunst CA, Brown MA: Mast cells are essential for early onset and severe disease in a murine model of multiple sclerosis. J Exp Med 2000, 191:813-22.
27. Lee DM, Friend DS, Gurish MF, Benoist C, Mathis D, Brenner MB: Mast cells: a cellular link between autoantibodies and inflammatory arthritis. Science 2002, 297:1689-92.
28. Feyerabend TB, Weiser A, Tietz A, Stassen M, Harris N, Kopf M, Radermacher P, Möller P, Benoist C, Mathis D, Fehling HJ, Rodewald H: Cre-mediated cell ablation contests mast cell contribution in models of antibody- and T cell-mediated autoimmunity. Immunity 2011, 35:832-44.
29. Reber LL, Marichal T, Galli SJ: New models for analyzing mast cell functions in vivo. Trends Immunol 2012, 33:613-25.
30. Ribatti D, Ennas MG, Vacca A, Ferreli F, Nico B, Orru S, Sirigu P: Tumor vascularity and tryptase-positive mast cells correlate with a poor prognosis in melanoma. Eur J Clin Invest 2003, 33:420-5.
31. Nonomura N, Takayama H, Nishimura K, Oka D, Nakai Y, Shiba M, Tsujimura A, Nakayama M, Aozasa K, Okuyama A: Decreased number of mast cells infiltrating into needle biopsy specimens leads to a better prognosis of prostate cancer. Br J Cancer 2007, 97:952-6.
32. Strouch MJ, Cheon EC, Salabat MR, Krantz SB, Gounaris E, Melstrom LG, Dangi-Garimella S, Wang E, Munshi HG, Khazaie K, Bentrem DJ: Crosstalk between mast cells and pancreatic cancer cells contributes to pancreatic tumor progression. Clin Cancer Res 2010, 16:2257-65.
33. Elpek GO, Gelen T, Aksoy NH, Erdogan A, Dertsiz L, Demircan A, Keles N: The prognostic relevance of angiogenesis and mast cells in squamous cell carcinoma of the oesophagus. J Clin Pathol 2001, 54:940-4.
34. Glimelius I, Edström A, Fischer M, Nilsson G, Sundström C, Molin D, Amini R, Enblad G: Angiogenesis and mast cells in Hodgkin lymphoma. Leukemia 2005, 19:2360-2.
35. Molica S, Vitelli G, Levato D, Giannarelli D, Vacca A, Cuneo A, Cavazzini F, Squillace R, Mirabelli R, Digiesi G: Increased serum levels of matrix metalloproteinase-9 predict clinical outcome of patients with early B-cell chronic lymphocytic leukaemia. Eur J Haematol 2003, 70:373-8.
36. Molica S, Vacca A, Crivellato E, Cuneo A, Ribatti D: Tryptase-positive mast cells predict clinical outcome of patients with early B-cell chronic lymphocytic leukemia. Eur J Haematol 2003, 71:137-9.
37. Galli SJ, Tsai M, Wershil BK, Tam SY, Costa JJ: Regulation of mouse and human mast cell development, survival and function by stem cell factor, the ligand for the c-kit receptor. Int Arch Allergy Immunol 1995, 107:51-3.
38. Gurish MF, Austen KF: Developmental origin and functional specialization of mast cell subsets. Immunity 2012, 37:25-33.
39. Huang B, Lei Z, Zhang G, Li D, Song C, Li B, Liu Y, Yuan Y, Unkeless J, Xiong H, Feng Z: SCF-mediated mast cell infiltration and activation exacerbate the inflammation and immunosuppression in tumor microenvironment. Blood 2008, 112:1269-79.
40. Norrby K, Jakobsson A, Sörbo J: Mast-cell secretion and angiogenesis, a quantitative study in rats and mice. Virchows Arch B Cell Pathol Incl Pathol 1989, 57:251-6.
41. Tóth-Jakatics R, Jimi S, Takebayashi S, Kawamoto N: Cutaneous malignant melanoma: correlation between neovascularization and peritumor accumulation of mast cells overexpressing vascular endothelial growth factor. Hum Pathol 2000, 31:955-60.
42. Blair RJ, Meng H, Marchese MJ, Ren S, Schwartz LB, Tonnesen MG, Gruber BL: Human mast cells stimulate vascular tube formation. Tryptase is a novel, potent angiogenic factor. J Clin Invest 1997, 99:2691-700.
43. Kinet J: The essential role of mast cells in orchestrating inflammation. Immunol Rev 2007, 217:5-7.
44. Saleem SJ, Martin RK, Morales JK, Sturgill JL, Gibb DR, Graham L, Bear HD, Manjili MH, Ryan JJ, Conrad DH: Cutting edge: mast cells critically augment myeloid-derived suppressor cell activity. J Immunol 2012, 189:511-5.
45. Rüger B, Dunbar PR, Hasan Q, Sawada H, Kittelberger R, Greenhill N, Neale TJ: Human mast cells produce type VIII collagen in vivo. Int J Exp Pathol 1994, 75:397-404.
46. Ribatti D: Mast cells and macrophages exert beneficial and detrimental effects on tumor progression and angiogenesis. Immunol Lett 2013, 152:83-8.
47. Grimbaldeston MA, Chen C, Piliponsky AM, Tsai M, Tam S, Galli SJ: Mast cell-deficient W-sash c-kit mutant Kit W-sh/W-sh mice as a model for investigating mast cell biology in vivo. Am J Pathol 2005, 167:835-48.
48. Pittoni P, Tripodo C, Piconese S, Mauri G, Parenza M, Rigoni A, Sangaletti S, Colombo MP: Mast cell targeting hampers prostate adenocarcinoma development but promotes the occurrence of highly malignant neuroendocrine cancers. Cancer Res 2011, 71:5987-97.
49. Soucek L, Lawlor ER, Soto D, Shchors K, Swigart LB, Evan GI: Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors. Nat Med 2007, 13:1211-8.
50. Gounaris E, Erdman SE, Restaino C, Gurish MF, Friend DS, Gounari F, Lee DM, Zhang G, Glickman JN, Shin K, Rao VP, Poutahidis T, Weissleder R, McNagny KM, Khazaie K: Mast cells are an essential hematopoietic component for polyp development. Proc Natl Acad Sci USA 2007, 104:19977-82.
51. Yang F, Ingram DA, Chen S, Zhu Y, Yuan J, Li X, Yang X, Knowles S, Horn W, Li Y, Zhang S, Yang Y, Vakili ST, Yu M, Burns D, Robertson K, Hutchins G, Parada LF, Clapp DW: Nf1-dependent tumors require a microenvironment containing Nf1+/- and c-kit-dependent bone marrow. Cell 2008, 135:437-48.
52. Starkey JR, Crowle PK, Taubenberger S: Mast-cell-deficient W/Wv mice exhibit a decreased rate of tumor angiogenesis. Int J Cancer 1988, 42:48-52.
53. Wedemeyer J, Galli SJ: Decreased susceptibility of mast celldeficient Kit(W)/Kit(W-v) mice to the development of 1, 2-dimethylhydrazine-induced intestinal tumors. Lab Invest 2005, 85:388-96.
54. Wasiuk A, Dalton DK, Schpero WL, Stan RV, Conejo-Garcia JR, Noelle RJ: Mast cells impair the development of protective anti-tumor immunity. Cancer Immunol Immunother 2012, 61:2273-82.
55. Rabenhorst A, Schlaak M, Heukamp LC, Förster A, Theurich S, Bergwelt-Baildon M von, Büttner R, Kurschat P, Mauch C, Roers A, Hartmann K: Mast cells play a protumorigenic role in primary cutaneous lymphoma. Blood 2012, 120:2042-54.
56. Purwar R, Schlapbach C, Xiao S, Kang HS, Elyaman W, Jiang X, Jetten AM, Khoury SJ, Fuhlbrigge RC, Kuchroo VK, Clark RA, Kupper TS: Robust tumor immunity to melanoma mediated by interleukin-9-producing T cells. Nat Med 2012, 18:1248-53.
57. Borg C, Terme M, Taïeb J, Ménard C, Flament C, Robert C, Maruyama K, Wakasugi H, Angevin E, Thielemans K, Le Cesne A, Chung-Scott V, Lazar V, Tchou I, Crépineau F, Lemoine F, Bernard J, Fletcher JA, Turhan A, Blay J, Spatz A, Emile J, Heinrich MC, Mécheri S, Tursz T, Zitvogel L: Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J Clin Invest 2004, 114:379-88.
58. Benson DM, Yu J, Becknell B, Wei M, Freud AG, Ferketich AK, Trotta R, Perrotti D, Briesewitz R, Caligiuri MA: Stem cell factor and interleukin-2/15 combine to enhance MAPK-mediated proliferation of human natural killer cells. Blood 2009, 113:2706-14.
59. Dudeck A, Dudeck J, Scholten J, Petzold A, Surianarayanan S, Köhler A, Peschke K, Vöhringer D, Waskow C, Krieg T, Müller W, Waisman A, Hartmann K, Gunzer M, Roers A: Mast cells are key promoters of contact allergy that mediate the adjuvant effects of haptens. Immunity 2011, 34:973-84.
60. Lilla JN, Chen C, Mukai K, BenBarak MJ, Franco CB, Kalesnikoff J, Yu M, Tsai M, Piliponsky AM, Galli SJ: Reduced mast cell and basophil numbers and function in Cpa3-Cre; Mcl-1fl/fl mice. Blood 2011, 118:6930-8.